3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Recurrence
2
Small Cell Lung Carcinoma
1
Recurrent Squamous Cell Lung Carcinoma
1
Rectal Neoplasms
1
Pleural Effusion, Malignant
1
Ovarian Neoplasms
1
MET Positive
1
Lung Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
106
Pemetrexed
74
Paclitaxel
58
Cisplatin
52
Erlotinib Hydrochloride
51
Radiotherapy
49
Docetaxel
43
Gemcitabine
41
Bevacizumab
41
pembrolizumab
30
Nivolumab
25
Radiosurgery
21
Etoposide
20
durvalumab
13
Cetuximab
13
Specimen Handling
12
Ipilimumab
12
Magnetic Resonance Spectroscopy
11
Gefitinib
11
Vinorelbine
10
Taxes
10
Radiation
10
Albumin-Bound Paclitaxel
10
osimertinib
9
Biopsy
9
vandetanib
8
Topotecan
7
Platinum
7
Irinotecan
7
Drug Therapy
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lung Neoplasms
×
rilotumumab
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts